Newswise — New Brunswick, N.J., April 14, 2021 – Rutgers Cancer Institute of New Jersey has received a $1.3 million, five-year grant from the National Cancer Institute (1T32CA257957) to support the Cancer Metabolism and Growth and Tumor Host Interactions Training Program. The program, which will focus on providing postdoctoral candidates the highest quality training and research experience, leverages the unique research strengths and resources of New Jersey’s only NCI-designated Comprehensive Cancer Center to provide translational research training in the area of cancer metabolism.
As part of the program, two postdoctoral trainees will participate in co-curricular and professional career development activities and receive training from faculty members at Rutgers Cancer Institute who have active, well-funded research programs and extensive mentoring experience. Eligible postdoctoral candidates must have an interest in collaborative translational research in cancer metabolism and tumor-host interactions and be committed to a two-year, rigorous training program. High achieving postdoctoral fellows may be supported for an additional third year of training through other funding sources.
“Through the Cancer Metabolism and Growth and Tumor Host Interactions Training Program, we leverage the outstanding environment for training in basic, clinical, behavioral and population-based cancer research at Rutgers Cancer Institute of New Jersey to provide postdoctoral candidates with the highest quality training and research experience,” noted Sunita Chaudhary, PhD, director of research education at Rutgers Cancer Institute. “We look forward to welcoming candidates who are excited to work towards making scientific advances in the areas of cancer metabolism and contribute to impactful scientific discoveries and clinical progress.”
Principal Investigators on the grant include Wei-Xing Zong, PhD, co-leader of the Cancer Metabolism and Growth Research Program at Rutgers Cancer Institute, John L. Colaizzi, PhD, RPh, professor at the Ernest Mario School of Pharmacy at Rutgers University and Yibin Kang PhD, associate director for Consortium Research at Rutgers Cancer Institute and Warner-Lambert/Parke Davis Professor of Molecular Biology at Princeton University.
For additional information and to learn how to apply, visit the program overview page: https://cinj.org/education/cancer-metabolism-and-growth-and-tumor-host-interactions-t32-training-grant
About Rutgers Cancer Institute of New Jersey
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.